
IDEX (IEX) Stock Forecast & Price Target
IDEX (IEX) Analyst Ratings
Bulls say
IDEX is a strong investment opportunity with a focus on sustainable growth through its integrated strategy and positive long-term book-to-bill ratio, particularly in the growing life sciences industry. The company's recent joint venture and potential for acquisitions demonstrate its commitment to capital deployment and future growth. However, there may be potential risks related to the company's reliance on AI adoption and datacenter capex. Overall, IDEX offers a high-margin business, favorable market trends, and strong financial performance, making it a top pick for investors.
Bears say
IDEX is facing risks from a mixed short-cycle business environment and potential macro uncertainties in its growth platforms, which could hinder its cash EPS and result in a scenario where shares trade at a 20% discount to peers, valuing it at $160. An additional risk lies in the company's short replenishment cycle, which could limit its visibility for the quarter and the year. Furthermore, portfolio rationalization efforts through the 80/20 strategy could lead to the premature exit of businesses, potentially hindering long-term growth opportunities. Overall, these factors contribute to a negative outlook on IDEX's stock in the near term.
This aggregate rating is based on analysts' research of IDEX and is not a guaranteed prediction by Public.com or investment advice.
IDEX (IEX) Analyst Forecast & Price Prediction
Start investing in IDEX (IEX)
Order type
Buy in
Order amount
Est. shares
0 shares